Market Overview

UPDATE: JP Morgan Raises PT on Pfizer on Takeaways from Meeting with Management

Share:
Related PFE
Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place
Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts
Tracking Kahn Brothers Portfolio - Q4 2015 Update (Seeking Alpha)

JP Morgan maintained Pfizer (NYSE: PFE) with an Overweight rating and raised the price target from $31.00 to $32.00.

JP Morgan analyst Chris Schott commented, "Overall, we see several interesting assets in Pfizer's pipeline beyond Eliquis and Xeljanz (most notably PD-991) and believe we are beginning to see results from the company's refocused R&D efforts. In addition, we continue to believe that a larger break-up of Pfizer remains a distinct possibility, particularly if the company's core pharmaceutical portfolio is able to generate sustained growth over time."

Pfizer closed at $27.99 on Tuesday.

Latest Ratings for PFE

DateFirmActionFromTo
Jan 2016JefferiesMaintainsBuy
Dec 2015Atlantic EquitiesInitiates Coverage onOverweight
Dec 2015BarclaysAssumesEqual-weight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters